Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jan R. Mead is active.

Publication


Featured researches published by Jan R. Mead.


Journal of Parasitology | 1995

A NEW METHOD FOR EVALUATING EXPERIMENTAL CRYPTOSPORIDIAL PARASITE LOADS USING IMMUNOFLUORESCENT FLOW CYTOMETRY

Michael J. Arrowood; Margaret R. Hurd; Jan R. Mead

A flow cytometric method for the quantification of Cryptosporidium parvum oocysts in stool specimens was developed to replace conventional microscopic immunofluorescent assays. Fecal pellets were collected from control (uninfected) severe combined immune-deficient mice, suspended in 2.5% potassium dichromate at a ratio of 400 microliter per pellet, and homogenized by vortexing. Purified oocytes were added to the samples (10(5), 10(4), 10(3), and 10(2)/ml). Aliquots (200 microliters) of the vortexed samples were centrifuged over microscale discontinuous sucrose gradients. The oocyst-containing fractions were collected, washed, and incubated with an oocyst-specific monoclonal antibody (labeled with fluorescein isothiocyanate) for 30 min at 37 degrees C. Sample volumes were adjusted to 600 microliters with phosphate-buffered saline and assayed by using logical gating of forward/side scatter and fluorescence signal on a flow cytometer. Seeded samples showed a linear correlation with the number of oocysts recovered from the gradients. Analyses of stool samples from chronically infected mice demonstrated that the flow cytometry method was approximately 10 times more sensitive than conventional immunofluorescent assays.


Journal of Parasitology | 1998

Susceptibility differences to Cryptosporidium parvum infection in two strains of gamma interferon knockout mice.

Jan R. Mead; Xiangdong You

Differences in susceptibility to cryptosporidial infections were investigated between 2 strains of gamma interferon knockout (GKO) mice. Male C57BL/6J-Ifg and BALB/c-Ifg (GKO) mice, ages 8-10 wk, were inoculated with infectious oocysts at various doses. C57BL/6J-Ifg mice developed overwhelming infections and died 9-12 days after infection. Low inoculum doses (1 x 10(3)) did not increase the survival time significantly. The infection intensity in C57BL/6J-Ifg mice inoculated with 1 x 10(5) oocysts/mouse increased markedly on day 4 postinfection (PI) and continued to increase significantly over the next 6-7 days. Most of the C57BL/6J-Ifg mice exceeded 15% weight loss and died by day 10 PI. In contrast, BALB/c-Ifg mice developed moderate infections from which they recovered. The average parasite load in the BALB/c-Ifg mice was 100 times lower than in C57BL/6J-Ifg mice. Mice survived until termination of the experiment (39 days) even when 1 x 10(6) oocysts per mouse were used for inoculation. BALB/c-Ifg mice did not exhibit significant weight loss (or difference in stool consistency). These 2 mouse strains make excellent models for studying differences in recovering and nonrecovering immune mechanisms.


Journal of Parasitology | 2002

Susceptibility to Cryptosporidium parvum Infections in Cytokine- and Chemokine- Receptor Knockout Mice

Lori D. Campbell; Julie Stewart; Jan R. Mead

To determine the role of cytokines and a chemokine receptor in the susceptibility to, and outcome of, infection, 4 different knockout mice (IL-4, IL-10, IL-12, and CCR5) were infected with Cryptosporidium parvum and monitored for infection intensity by collection of fecal pellets from individual mice. Because adult immunocompetent mice are refractory to infection, wild-type mice on the same background as the knockout mice (C57BL/6) were used as a negative control. No infection was detected over a 4-wk time period in IL-4, IL-10, and CCR5 knockout mice inoculated with 106 oocysts. IL-12 knockout mice inoculated with as little as 100 oocysts shed up to 10,000 oocysts/100 μl of feces on the peak infection day (day 8) and were able to fully recover by 2 wk after infection. IL-12 is an important inducer of IFN-γ, which probably accounted for susceptibility to infection. Previous studies using IFN-γ knockout mice have shown strain-related differences in infection intensity and outcome, with increased parasite loads and decreased survival among IFN-γ knockout mice on a C57BL/6 background compared with those on a BALB/c background. Similar results were observed in IL-12 knockout mice on a BALB/c background, which exhibited little or no infection, despite higher levels of inoculation (106 oocysts/mouse).


Journal of Parasitology | 2000

CYTOKINE EXPRESSION AND SPECIFIC LYMPHOCYTE PROLIFERATION IN TWO STRAINS OF CRYPTOSPORIDIUM PARVUM-INFECTED γ-INTERFERON KNOCKOUT MICE

L.Mary Smith; María-Teresa Bonafonte; Jan R. Mead

Differences in the immune response between 2 strains of interferon-γ knockout mice (BALB/c-GKO and C57BL/6-GKO) infected with Cryptosporidium parvum were examined because the course of infection among these 2 strains is markedly different. Infection of the BALB/c-GKO with C. parvum (2 × 106 oocysts/mouse) resulted in slight weight loss, oocyst shedding, and recovery from infection by 2 wk postinfection (PI). Infection with 100 oocysts in the C57BL/6-GKO mice resulted in significant weight loss, oocyst shedding, and death by day 10 PI. Splenocytes from infected mice were able to proliferate in a dose-dependent manner to soluble C. parvum-sporozoite antigen (SAg). In vitro stimulation with SAg resulted in an increase in interleukin (IL)-2, IL-4, IL-5, and tumor necrosis factor-α mRNA cytokine expression from splenocytes of infected BALB/c-GKO mice. In contrast, only IL-5 mRNA expression was increased in the splenocytes from C. parvum-infected C57BL/6-GKO mice. Phenotypic analysis indicated no significant differences in the splenic cell populations. Previous studies indicated that susceptibility to C. parvum is dependent on CD4+ T cells and interferon-γ production. The present study indicates that although both of these strains of knockout mice become infected with C. parvum, resolution of infection may be in part dependent on the expression of Th2 cytokines.


Antiviral Research | 1991

Effect of human, recombinant interleukin 2 on Punta Toro virus infections in C57BL/6 mice.

Jan R. Mead; Roger A. Burger; L.Jeanne Yonk; J. Coombs; Reed P. Warren; Meir Kende; John W. Huggins; Robert W. Sidwell

The effect of human recombinant interleukin-2 (rIL-2) on Punta Toro virus (PTV) infection was investigated in C57BL/6 mice. Immunologic and viral parameters were assessed after mice were treated i.p. with rIL-2 for 5 days. Treatment of mice with 25000 and 12500 units/mouse of rIL-2 resulted in significant inhibition of the disease as indicated by increases in survival of mice as well as decreases in liver and serum virus titers. Serum glutamic oxalic acid and pyruvic acid transaminase levels were also lowered indicating reduced liver damage. Murine IL-2 production returned to normal or above-normal levels in rIL-2 treated mice. Natural killer cell activity was also moderately stimulated by rIL-2 treatment. Significant amounts of interferon were not detected in the sera of treated mice. Weight gain and survival rates were similar for both toxicity and normal controls indicating that rIL-2 treatments had no toxic effect.


Antiviral Research | 1992

Elucidation of mode of retroviral-inhibitory effects of imexon through use of immune competent and severe combined immune deficiency (SCID) mice.

John D. Morrey; Jan R. Mead; Reed P. Warren; Kevin M. Okleberry; Roger A. Burger; Robert W. Sidwell

Mice infected with various tumor retroviruses have been used as models for evaluating therapeutic substances for the treatment of some cancers, and more recently, for human immunodeficiency virus (HIV) infection, the causative agent of acquired immune deficiency syndrome (AIDS). Consequently, there is a need to determine the ability of biological response modifiers (BRMs) to specifically reduce virus-infected cells, as compared to their non-specific anti-proliferative effects. To address this need, a BRM, imexon, was evaluated in this study using three strains of mice having different Friend virus (FV)-specific immunological capabilities. The first strain, (B10.A x A/WySn)F1, was genetically capable of producing FV-specific neutralization and cytotoxic antibodies, the second, Balb/c, was not, and the third, SCID mice, lacked functional T and B cell immunity. Imexon treatment reduced virally-induced splenomegaly in all 3 strains; however, the concentration of splenic viral infectious centers (IC) were not affected. Since imexon was efficacious in reducing splenomegaly in SCID mice, the mode of action was concluded to not require functional T or B cell immunity. The observation that imexon did not affect splenic IC titers also suggested that imexon did not specifically eliminate virally infected cells, but may have functioned by other mechanisms. This study also demonstrated the use of various mouse strains as a strategy for delineating the modes of action of BRMs against murine retroviral infections.


The Journal of Infectious Diseases | 1991

Chronic Cryptosporidium parvum Infections in Congenitally Immunodeficient SCID and Nude Mice

Jan R. Mead; Michael J. Arrowood; Robert W. Sidwell; Mark C. Healey


Journal of Antimicrobial Chemotherapy | 1998

In-vitro activities of paromomycin and lasalocid evaluated in combination against Cryptosporidium parvum.

Xiangdong You; Raymond F. Schinazi; Michael J. Arrowood; Marisa Lejkowski; Amy S. Juodawlkis; Jan R. Mead


Biotechnology therapeutics | 1993

Effect of immunomodulators in the hu-PBL-SCID mouse model

Jan R. Mead; Roger A. Burger; John D. Morrey; Reed P. Warren; Kevin M. Okleberry; Robert W. Sidwell


Recent Adv Chemother | 1992

Experiences with biological response modifiers in animal models for AIDS

Robert W. Sidwell; Kevin M. Okleberry; Reed P. Warren; Roger A. Burger; Jan R. Mead; John D. Morrey

Collaboration


Dive into the Jan R. Mead's collaboration.

Top Co-Authors

Avatar

Michael J. Arrowood

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Amanda R. Freeman

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge